13 March 2019 | News
This medication is a mineral supplement used to treat or prevent low amounts of potassium in the blood
Zydus Cadila is an innovative, global pharmaceutical company, has received the final approval from the USFDA to market Potassium Chloride Extended-Release Capsules USP (US RLD – Micro-K® Extended-Release Capsules), 8 mEq (600 mg) and 10 mEq (750 mg). It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad.
This medication is a mineral supplement used to treat or prevent low amounts of potassium in the blood. Potassium helps your cells, kidneys, heart, muscles, and nerves work properly. Some conditions that can lower the body's potassium level include severe prolonged diarrhoea and vomiting, hormone problems such as hyperaldosteronism, or treatment with ‘water pills’/diuretics.
The group now has 254 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04.